IRIS
CORREALE, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1614
NA - Nord America 807
AS - Asia 280
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 1
OC - Oceania 1
SA - Sud America 1
Totale 2707
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 805
IE - Irlanda 750
SE - Svezia 363
UA - Ucraina 270
CN - Cina 222
IT - Italia 93
AT - Austria 51
FI - Finlandia 32
TR - Turchia 29
IN - India 27
FR - Francia 17
DE - Germania 11
GB - Regno Unito 10
BE - Belgio 7
NL - Olanda 3
CA - Canada 2
ES - Italia 2
EU - Europa 2
JP - Giappone 2
RU - Federazione Russa 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
BR - Brasile 1
EG - Egitto 1
HR - Croazia 1
PL - Polonia 1
RO - Romania 1
Totale 2707
Salva come PNG Salva come JPEG
Città #
Dublin 750
Nyköping 233
Chandler 187
Jacksonville 170
Dearborn 72
Princeton 61
Nanjing 60
Vienna 51
Wilmington 45
Beijing 36
Nanchang 22
Helsinki 21
San Mateo 17
Tianjin 15
Des Moines 14
Shenyang 11
Foggia 9
Rome 9
Jiaxing 8
Renton 8
Brussels 7
Changsha 7
Hangzhou 7
Kunming 7
Lund 7
Palermo 7
Stevenage 7
Woodbridge 7
Ann Arbor 6
Gesualdo 6
Guangzhou 6
Hebei 6
Jinan 6
Acerra 5
Bari 5
Ningbo 5
Changchun 4
Lanzhou 4
Messina 4
Norwalk 4
Philadelphia 4
San Severo 4
Apricena 3
Bisceglie 3
Borås 3
Los Angeles 3
Redwood City 3
Shanghai 3
Stimigliano 3
Taglio Di Po 3
Zhengzhou 3
Augusta 2
Dallas 2
Hanover 2
Hefei 2
Hilden 2
Kolkata 2
Martina Franca 2
New Delhi 2
Orange 2
Paris 2
Rockville 2
Taizhou 2
Valle 2
Agordo 1
Aprilia 1
Arzano 1
Benetutti 1
Bitonto 1
Boardman 1
Cairo 1
Chengdu 1
Cirié 1
Clearwater 1
Frankfurt am Main 1
Fuzhou 1
Glasgow 1
Haikou 1
Hunedoara 1
Jackson 1
Kilcoy 1
Latina 1
Leawood 1
London 1
New York 1
Novokuznetsk 1
Oristano 1
Peschici 1
Porto 1
Raleigh 1
Redmond 1
Reggio Emilia 1
Reno 1
Sacramento 1
San Francisco 1
Sanayi 1
Santa Rosa 1
Toronto 1
Valenzano 1
Walnut 1
Totale 2013
Salva come PNG Salva come JPEG
Nome #
Alcohol-induced cardiac disease 88
Tissue Doppler Imaging predicts central sleep apnea in patients with chronic heart failure: data from the Daunia Registry 80
ABCB1 SNP rs4148738 modulation of apixaban interindividual variability 78
EXPRESS: Don't stop at first glance; pulmonary artery angiosarcoma mimicking chronic thromboembolic pulmonary hypertension 77
Typical Takotsubo syndrome and McConnell's phenomenon: What else lies beneath? 74
"PAFIYAMA" syndrome; further evidence on a novel clinical entity 70
Angiotensin-converting enzyme inhibitors, angiotensin II receptors antagonists, beta-blockers and ivabradine as supportive therapy in pulmonary hypertension: Drug safety and tolerability 70
Late onset of coronary vasospasm after administration of methyl-ergometrine for gynecologic bleeding. 69
Cardiopulmonary exercise test predicts right heart catheterization 68
Chronic thromboembolic pulmonary hypertension. 66
Tako-Tsubo cardiomyopathy in a teen girl with pheochromocytoma. 65
Inferior ST-Elevation Acute Myocardial Infarction or an Inferior-Lead Brugada-like Electrocardiogram Pattern Associated With the Use of Pregabalin and Quetiapine? 65
Recurrent Tako-Tsubo cardiomyopathy apparently induced by opposite triggers 64
Macitentan Use in a Neurofibromatosis Type 1 Patient With Pulmonary Hypertension and External Jugular Phlebectasia 61
Liver disease and heart failure: Back and forth 61
Delirium in heart failure 61
Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis 60
Redefining biomarkers in heart failure 60
Tako-Tsubo cardiomyopathy recurrence in an elderly woman firstly diagnosed with acute myocardial infarction: How many cold cases to be reclassified? 57
Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis 56
Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy 55
HIV-associated pulmonary arterial hypertension: from bedside to the future 54
SAT0325 Nailfold capillaroscopic changes in patients with idiopathic and systemic sclerosis-related pulmonary arterial ipertension 51
Fenofibrate and Dyslipidemia: Still a Place in Therapy? 50
Tako-Tsubo cardiomyopathy or allergic acute coronary syndrome: that is the question. 48
"ischemic" ST elevation in a woman with left ventricular hypertrophy 48
Echocardiographic score for prediction of pulmonary hypertension at catheterization: The Daunia Heart Failure Registry 46
Gastrointestinal bleeding and coagulation disorders in a patient with left-ventricular assist device 44
Novel AKAP9 mutation and long QT syndrome in a patient with torsades des pointes 44
Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry 44
Biomarkers in cardiorenal syndrome 44
Advanced heart failure: non-pharmacological approach 43
Influence of Heart Rate on Left and Right Ventricular Longitudinal Strain in Patients with Chronic Heart Failure 41
Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry 40
Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: Where do we stand? 39
Cardiac contractility modulation in left ventricular systolic dysfunction: trick or treat? 39
Liver disease and heart failure: an uptodate 38
Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials 38
COMPASS vs PEGASUS approach in a comparative budget impact analysis 38
Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management 36
Disease-modifier Drugs in Patients with Advanced Heart Failure: How to Optimize Their Use? 35
Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure 35
The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic 34
Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation 33
Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization 32
ABCB1 SNP rs4148738 modulation of apixaban interindividual variability 32
Predictors of clinical improvement with sacubitril/valsartan in a real world population with chronic heart failure 31
Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure 31
The thromboembolism in COVID-19: the unsolved problem 30
Chronic thromboembolic pulmonary hypertension mimicking coronary artery disease 30
Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan 30
Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies 29
Delirium in heart failure 29
Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? 27
Infection, atherothrombosis and thromboembolism beyond the COVID-19 disease: what similar in physiopathology and researches 27
Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials 27
New Targets in Heart Failure Drug Therapy 25
Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure 24
Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone 24
Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension 22
Effects of Sacubitril/Valsartan on the Renal Resistance Index 21
Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? 21
Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients 20
Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction 19
LEAP Virtual Visit Assessment (VIVA): A structured protocol for virtual visits for patients with heart failure 15
Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study) 14
Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender 13
SGLT2 Inhibitors: Statins or ACE-Inhibitors of the 21st Century? 4
Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest 3
Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan 3
Totale 2950
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11330
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11330
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019259 133320 4943 386 1271235
2019/2020382 682862 4051 679 5014443
2020/2021371 5074212 433 5154 525610
2021/2022412 172113 7014 1138 49866105
2022/20231401 117698338 31104 292 81110440
Totale 2950